Ascending Dose Study of the Safety and Tolerability of REGN6490 in Healthy Volunteers

Summary

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN6490 in healthy adult participants The secondary objectives of the study are to: * Characterize the pharmacokinetic (PK) profile of single IV and SC doses of REGN6490 in healthy adult participants * Assess immunogenicity of REGN6490 in healthy adult participants dosed with a single IV or SC dose of REGN6490

Timeline

Start

2020-11-19

Primary completion

2021-06-01

Completion

2021-06-01

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Drugs

Indications

No indication recorded.